Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for okt3 (compound)
Most Correlated Studies
- CD4+ splenocyte gene expression in response to treatment with teplizumab or hIg
- CD4+ T cells stimulated and then restimulated in the presence or absence of natalizumab
- Blood of type 1 diabetes patients who responded or did not respond to teplizumab
- Influence of anti-CD25 mAb on the transcriptome of activated PBMC
- T-cells from healthy donor-derived PBMC after treatment with anti-CD3 antibodies
Most Relevant Literature
- Nanovesicles released by OKT3 hybridoma express fully active antibodies.
- Peripheral T-cell lymphoma immunophenotype in a patient with a history of Muromonab-CD3 therapy: A c…
- Genetic code expansion in E. coli enables production of a functional 'ready-to-click' T cell recepto…
- Optimizing rAAV6 transduction of primary T cells for the generation of anti-CD19 AAV-CAR-T cells.
- Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activ…
Most Relevant Clinical Trials
- Oral OKT3 in Combination With Beta-D-Glucosylceramide
- Oral OKT3 for the Treatment of Active Ulcerative Colitis
- Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody (mAb)in Patients With the…
- Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanc…
- Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditio…
